In last trading session, Adial Pharmaceuticals Inc (NASDAQ:ADIL) saw 105.14 million shares changing hands with its beta currently measuring 1.54. Company’s recent per share price level of $2.33 trading at $1.2 or 106.19% at ring of the bell on the day assigns it a market valuation of $9.44M. That closing price of ADIL’s stock is at a discount of -500.86% from its 52-week high price of $14.00 and is indicating a premium of 67.38% from its 52-week low price of $0.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.24 million shares which gives us an average trading volume of 4.01 million if we extend that period to 3-months.

Adial Pharmaceuticals Inc (NASDAQ:ADIL) trade information

Upright in the green during last session for gaining 106.19%, in the last five days ADIL remained trading in the green while hitting it’s week-highest on Wednesday, 04/10/24 when the stock touched $2.33 price level, adding 14.96% to its value on the day. Adial Pharmaceuticals Inc’s shares saw a change of 25.27% in year-to-date performance and have moved 87.90% in past 5-day. Adial Pharmaceuticals Inc (NASDAQ:ADIL) showed a performance of 16.50% in past 30-days. Number of shares sold short was 0.11 million shares which calculate 0.01 days to cover the short interests.

Adial Pharmaceuticals Inc (ADIL) estimates and forecasts

Statistics highlight that Adial Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -17.38% of value to its shares in past 6 months, showing an annual growth rate of 66.19% while that of industry is 13.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 87.30% in the current quarter and calculating -136.50% decrease in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.36% during past 5 years.

ADIL Dividends

Adial Pharmaceuticals Inc is more likely to be releasing its next quarterly report in May and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Adial Pharmaceuticals Inc (NASDAQ:ADIL)’s Major holders

Insiders are in possession of 9.80% of company’s total shares while institution are holding 15.91 percent of that, with stock having share float percentage of 17.64%. Investors also watch the number of corporate investors in a company very closely, which is 15.91% institutions for Adial Pharmaceuticals Inc that are currently holding shares of the company. Manchester Capital Management, LLC is the top institutional holder at ADIL for having 48098.0 shares of worth $10014.0. And as of Jun 29, 2023, it was holding 3.95% of the company’s outstanding shares.

The second largest institutional holder is Vanguard Group Inc, which was holding about 8134.0 shares on Jun 29, 2023. The number of shares represents firm’s hold over 0.67% of outstanding shares, having a total worth of $1693.0.

On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 8134.0 shares of worth $1693.0 or 0.67% of the total outstanding shares. The later fund manager was in possession of 2915.0 shares on May 30, 2023, making its stake of worth around $766.0 in the company or a holder of 0.24% of company’s stock.